ERBB2 and non-small cell lung carcinoma: However, considering the complexity of this type of disease, together with the results already realised in the EGFR Ex20ins NSCLC disease, where the current standard is represented by the addition of amivantamab to the standard chemotherapy, we believe that future developments in the research of HER2 MUT NSCLC will be around the design of the following new combinations: TKI or ADC plus chemotherapy +/− ICI [129].